Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease

Mostrar otras versiones (1)

Repurposing FDA-approved inhibitors able to prevent infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could provide a rapid path to establish new therapeutic options to mitigate the effects of coronavirus disease 2019 (COVID-19). Proteolytic cleavages of the spike (S) protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Kreutzberger, Alex J. B., Sanyal, Anwesha, Ojha, Ravi, Pyle, Jesse D., Vapalahti, Olli, Balistreri, Giuseppe, Kirchhausen, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Virus-Cell Interactions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513479/
https://www.ncbi.nlm.nih.gov/pubmed/34406858
http://dx.doi.org/10.1128/JVI.00975-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513479/
https://www.ncbi.nlm.nih.gov/pubmed/34406858
http://dx.doi.org/10.1128/JVI.00975-21

Ejemplares similares